Lexaria Bioscience Corp. (LEXX) Stock Score, Valuation & Financial Research
Lexaria Bioscience Corp. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 26/100.
Quick answer for LEXX
Lexaria Bioscience Corp. currently has a Wall Street Score of 26/100. The stored market price is $3.97. Its financial score is 29/100. Its valuation score is 0/100. The latest WSS change is +1.0 points. These figures are a research snapshot, not a buy or sell recommendation.
What Lexaria Bioscience Corp. does
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A
LEXX financial snapshot
- Wall Street Score:
- 26/100
- Current price:
- $3.97
- Market capitalization:
- $6.6M
- Revenue:
- $194K
- Net income:
- $-7.7M
- Free cash flow:
- $-10.5M
- Cash:
- $3.5M
- Total debt:
- $87K
- EPS:
- -5.32
- Financial score:
- 29/100
- Valuation score:
- 0/100
- Revenue score:
- 20/100
What stands out
- Reported year-over-year revenue growth is -0.7%.
- Free cash flow is $-10.5M, showing cash burn in the current stored period.
- The balance sheet shows $3.5M of cash versus $87K of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +1.0 points: LEXX increased 1 points because Asset improved by 9.9 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 29/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-13.
How to research LEXX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.